PTD-DBM
A Wnt signalling activator peptide that inhibits the CXXC5-Dvl interaction to stimulate hair follicle regeneration and wound healing through beta-catenin pathway activation.
Community Rating
No ratings yet
Compound Profile
PTD-DBM
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. PTD-DBM is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Activates Wnt/beta-catenin signalling by blocking the CXXC5-Dvl interaction - a specific target not addressed by other hair loss compounds
- Stimulates hair follicle regeneration in androgenetic alopecia and alopecia areata models
- Promotes the anagen (growth) phase of the hair cycle
- PTD-DBM is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Activates Wnt/beta-catenin signalling by blocking the CXXC5-Dvl interaction - a specific target not addressed by other hair loss compounds
- Stimulates hair follicle regeneration in androgenetic alopecia and alopecia areata models
- Promotes the anagen (growth) phase of the hair cycle
- Synergistic with valproic acid (another Wnt activator) for enhanced hair follicle neogenesis
In Plain English
Simple summaryPTD-DBM is a synthetic chimeric peptide combining a protein transduction domain (PTD, for cell entry) with a beta-catenin binding domain-mimetic (DBM) designed to disrupt the Wnt/beta-catenin signaling pathway. Wnt/beta-catenin signaling is hyperactivated in many cancers and drives tumor growth, invasion, and cancer stem cell maintenance. By delivering a beta-catenin competing sequence inside cancer cells, PTD-DBM is designed to reduce beta-catenin's transcriptional activity and suppress tumor growth. It has been studied in cancer models where Wnt pathway inhibition shows efficacy, and also in hair follicle biology -- the Wnt pathway controls hair follicle cycling and is a target for hair loss treatment research.
- Activates Wnt/beta-catenin signalling by blocking the CXXC5-Dvl interaction - a specific target not addressed by other hair loss compounds
- Stimulates hair follicle regeneration in androgenetic alopecia and alopecia areata models
- Promotes the anagen (growth) phase of the hair cycle
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is PTD-DBM?
Tap any underlined term for an instant definition.
PTD-DBM is a synthetic cell-penetrating peptide designed to activate Wnt/beta-catenin signalling by specifically blocking the interaction between CXXC5 (a zinc-finger transcription factor) and Dvl (Dishevelled, a key intracellular Wnt pathway component). This targeted inhibition of a specific protein-protein interaction represents a mechanistically distinct approach to hair follicle regeneration compared to existing treatments like minoxidil (vasodilator) or finasteride (DHT inhibitor).
The Wnt/beta-catenin signalling pathway is absolutely critical for hair follicle development, cycling, and regeneration. During the normal hair cycle, Wnt signalling is activated in dermal papilla cells at the onset of the anagen (growth) phase, driving follicle activation from the telogen (resting) state. In models of androgenetic alopecia, this Wnt signalling is impaired - follicles fail to activate properly, anagen duration shortens, and hair miniaturisation progresses. Restoring Wnt pathway activity has been a long-standing goal of hair loss research.
CXXC5 functions as a negative feedback regulator of Wnt signalling - it is induced by Wnt activation and then inhibits further Wnt signal transduction by binding to and sequestering Dvl. This creates a self-limiting feedback loop. PTD-DBM, derived from the Dvl-binding motif (DBM) of CXXC5 combined with a protein transduction domain (PTD) for cell penetration, competes with endogenous CXXC5 for Dvl binding. By blocking CXXC5-Dvl interaction, PTD-DBM prevents this negative feedback, sustaining Wnt pathway activity.
The landmark study demonstrating PTD-DBM's hair regeneration effects showed that topical application to mouse skin, particularly when combined with valproic acid (a histone deacetylase inhibitor that also activates Wnt signalling via different mechanisms), produced significant hair follicle neogenesis from wounds - a phenomenon called wound-induced hair neogenesis that is normally restricted to young animals. Additionally, the PTD-DBM/valproic acid combination restored hair growth in a murine alopecia model.
The wound healing applications of PTD-DBM extend beyond hair follicles. Wnt signalling is broadly important for skin wound healing, driving keratinocyte migration, fibroblast activation, and ECM remodelling. Studies have shown that PTD-DBM application accelerates wound closure and improves healing quality, suggesting dual potential in hair loss and wound repair research.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on PTD-DBM. See all Healing & Recovery peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
PTD-DBM research is primarily preclinical. Most published data uses topical application in hair loss models.
Preclinical topical dose: 1-5 mg/mL applied to shaved scalp area, once daily Often combined with valproic acid (3 mM topical) for Wnt pathway synergy Research cycle: 3-4 weeks in published rodent studies Human equivalent dosing has not been established clinically
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
PTD-DBM has been studied primarily as a topical application to the scalp. Dissolve in an appropriate vehicle (DMSO/PBS or similar) for topical application. Apply to target area once daily. For injection protocols, reconstitute with bacteriostatic water and administer subcutaneously near the target area.
What the research doesn't show
PTD-DBM is a preclinical research tool -- no human trials are published. The Wnt/beta-catenin pathway has been extensively studied as a cancer target with multiple small molecules in clinical development, but pathway selectivity and toxicity (Wnt signaling is important in normal tissue homeostasis) have made it a challenging drug target. PTD-DBM's hair follicle research angle is separate from cancer development and may be its more near-term clinical application.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain PTD-DBM, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
PTD-DBM has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: activates wnt/beta-catenin signalling by blocking the cxxc5-dvl interaction - a specific target not addressed by other hair loss compounds.
The most commonly reported side effect in research subjects is limited human clinical data - primarily preclinical evidence in rodent models. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Other Wnt pathway inhibitors include porcupine inhibitors (WNT974, LGK-974) that block Wnt ligand secretion, and tankyrase inhibitors that stabilize beta-catenin destruction complexes. These small molecules target different points in the Wnt pathway than PTD-DBM's intracellular beta-catenin competition. FOXO4-DRI uses a similar CPP chimeric design concept for senolytic applications.
Compare PTD-DBM side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.